Cynapsus Therapeutics Inc. : Cynapsus Therapeutics' APL 130277

Cynapsus Therapeutics Inc. : Cynapsus Therapeutics' APL 130277 For
Parkinson's Chosen As One Of The Top Ten Neurology Projects To Watch
For 2012 
TORONTO -- (Marketwire) -- 10/29/12 --  
October 29, 2012 
-Independent Committee Selects Cynapsus' Novel Sublingual
formulation of Apomorphine, as One of the Most Promising CNS
TORONTO, CANADA - Cynapsus Therapeutics Inc. (CTH: TSX V) today
announced that its APL-130277 for Parkinson's was recognized as one of
the Top Ten Neurology Projects to Watch in 2012 by a joint selection
committee including Dr. Harry Tracy, a noted authority on
pharmacological interventions for diseases of the brain and editor of
the highly respected biotechnology publication NeuroPerspective, as
well as with Elsevier Business Intelligence, the publishers of In
Vivo, Startup and The Pink Sheet.   Cynapsus has been invited to
present the APL-130277 Project at Elsevier's Therapeutic Area
Partnerships Meeting taking place on November 28-30, 2012 at the
Westin Copley in Boston. 
Criteria for selection of the Top 10 Neurology Projects to Watch in

  * Large market, large unmet need, with increasing opportunity
  * History of the molecule and drug
  * Strong science
  * Strong company
  * Diversity of indications
  * Potential for new opportunities beyond the initial indications
  * Multi-level partnering opportunities, i.e., biotech to biotech
    as well as pharma to biotech

APL 130277 is a unique and innovative, sublingual thin film strip
formulation of apomorphine.  Apomorphine is an  approved drug
prescribed in the US, Europe and several  other  countries.  It  is 
administered  as a subcutaneous injection or infusion  to Parkinson's
patients experiencing daily "OFF" or motor fluctuation episodes. APL
130277 would provide patients with a convenient and more tolerable
alternative  to  multiple daily  injections.  As  a  new means of
delivering an approved   drug, this   clinical   stage  project  is 
expected  to  follow  a bioequivalence  regulatory and clinical path
which would culminate in a New Drug Approval application in 2015. 
"We  are humbled to be recognized from among several hundred worthy
neuroscience projects,  worldwide.  This  is  a  significant  honor 
and further independent validation  of the p
otential  of APL-130277.
This comes only a few months after receiving a significant grant from
The Michael J. Fox Foundation for Parkinson's Research  (MJFF)  to 
help  support  our next clinical study (CTH103). The MJFF Clinical 
Intervention  Award  was provided  through  the Edmond  J. Safra Core
Programs  for Parkinson's Research," said  Mr. Anthony Giovinazzo,
President and Chief  Executive  Officer  of  Cynapsus.   "Since  we
started  this project, we determined  that  there  are  a  large 
number of Parkinson's patients who would benefit  from needle-free
delivery of the drug.  This includes patients who want a  convenient
alternative to a very painful injection regimen, patients who have
resisted initiating therapy because of the needle issues, and the
increase in PD population  as  a result  of  the  growing  aging baby
boomer generation. These factors  combined  indicate  that  the 
number of Parkinson's patients worldwide could  potentially  increase
 2-to-3 fold  over  the  next  8 to 10 years. This significant 
potential unmet  medical need  coupled with  a short and lower risk
clinical  pathway would be of  interest to many in global and
specialty pharma, especially  given that  our pending  patent estate,
 when approved  and granted, would provide protection to 2031 at a
About Parkinson's Disease 
Parkinson's disease is a chronic, degenerative neurological disorder
that results from the loss of dopamine producing nerve cells in the
brain. Current treatments for Parkinson's disease are able to reduce
the symptoms of the disease but are not able to treat the underlying
neurodegenerative processes that lead to a decline in physical and
cognitive functions that affects some patients with Parkinson's
disease. It is estimated that over one million people in the United
States and 5 million people globally are living with Parkinson's
disease. According to the National Institute of Neurodegenerative
Disease and Stroke, the average age of onset is 60, although some
people are diagnosed at age 40 or younger. 
About Cynapsus Therapeutics 
Cynapsus  is  a  specialty  pharmaceutical  company  developing  the
only orally administered   convenient  (sublingual)  delivery  of  the
 only approved  drug (apomorphine)  to  treat  the  motor  symptoms 
of Parkinson's disease. Over one million  people in the United States 
and an estimated 5 million people globally suffer   from  
Parkinson's  disease. Parkinson's  disease  is  a  chronic  and
progressive  neurodegenerative disease  that  impacts  motor 
activity, and its prevalence  is increasing with the aging of  the
population. Based on the IMPACT Registry  Study and the results of 
Cynapsus' Global 500 Neurologists Survey, is estimated  that between 
25 percent and  50 percent of  patients experience "OFF episodes" in
which they have impaired movement or speaking capabilities. Current
medications  only control  the disease's symptoms, and  most drugs 
become less effective over time as the disease progresses. 
Cynapsus' lead drug candidate, APL 130277, is an easy to administer,
fast acting reformulation of an approved drug, apomorphine, used to
rescue patients from OFF episodes.  Cynapsus is focused on rapidly 
maximizing the value of APL 130277 by completing  pivotal studies in
advance of a  New Drug Application expected to be submitted   in  
2015. Cynapsus anticipates  out licensing  to  an  appropriate
pharmaceutical partner before such an application is submitted. 
More information about Cynapsus (CTH: TSX V) is available at and at  the  System  for  Electronic  Document 
Analysis and  Retrieval  (SEDAR) at 
About TA Partnerships 
Elsevier's 7th Annual Therapeutic Area Partnerships is the industry's
most targeted and efficient partnering meeting for life science
companies seeking partnerships in the top therapeutic areas: Oncology,
Cardiovascular/Metabolic, Neuroscience, Infectious, Inflammatory
Diseases and other hot therapeutic areas. Decision-makers focusing on
these therapeutic categories can meet to develop strategic alliances
in a personal and interactive setting that combines company
presentations, 1:1 meetings and networking functions. More
information is available at 
About Elsevier Business Intelligence 
Elsevier Business Intelligence, a global leader in the field of
healthcare industry information, provides business intelligence on
regulatory, business and reimbursement issues that are vital to the
healthcare industry. Through a range of products including
publications, conferences, e-learning, databases and reports,
Elsevier Business Intelligence places biopharma and medical device
professionals, and those who focus on these industries, at the
forefront of knowledge, by providing the perfect combination of news
and information together
with penetrating insight and analysis. Our
leading publications include PharmAsia News, IN VIVO and "The Pink
Sheet." For more information, visit: 
Forward Looking Statements 
This announcement contains "forward-looking statements" within the
meaning of
applicable Canadian securities legislation. Generally,
these forward- looking
statements can be identified by the use of
forward-looking terminology such as
"plans", "expects" or "does not
expect", "is expected", "budget", "scheduled",
"forecasts", "intends", "anticipates" or "does not anticipate", or
"believes" or variations of such words and phrases or state that
certain actions, events or results "may", "could", "would", "might" or
"will be taken",
"occur" or "be achieved". Forward-looking statements
are subject to known and
unknown risks, uncertainties and other
factors that may cause the actual results, level of activity,
performance or achievements of Cynapsus to be materially different
from those expressed or implied by such forward- looking
including but not limited to those risks and uncertainties
to Cynapsus' business disclosed under the heading "Risk and
Uncertainties" in
"Management's Discussion and Analysis of Operating
Results and Financial Condition" for the year ended December 31,
2011, and its other filings with the
various Canadian securities
regulators which are available online at Although
Cynapsus has attempted to identify important factors
that could cause
actual results to differ materially from those contained
forward-looking statements, there may be other factors that cause
results not to be as anticipated, estimated or intended. There can be
no assurance that such
statements will prove to be accurate, as
actual results and future events could
differ materially from those
anticipated in such statements. Accordingly, readers should not place
undue reliance on forward-looking statements. Cynapsus
does not
undertake to update any forward-looking statements, except in
accordance with applicable securities laws. 
This announcement is
distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and    
other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and     
originality of the information contained therein. 
Source: Cynapsus Therapeutics Inc. via Thomson Reuters ONE 
Contact Information
Cynapsus Therapeutics
Anthony Giovinazzo
President and CEO
(416) 703-2449 x225 
Andrew Williams
(416) 703-2449 x253
Press spacebar to pause and continue. Press esc to stop.